Mark Eisner - 15 Jul 2025 Form 4 Insider Report for Vir Biotechnology, Inc. (VIR)

Reporting relationship: EVP and Chief Medical Officer
Issuer ticker: VIR
Reported as of: 15 Jul 2025
Net transaction value: -$56,791
SEC form: 4
Accepted by SEC: 17 Jul 2025, 18:46:56 UTC
Prior SEC filing: 25 Feb 2025
Next SEC filing: 24 Feb 2026
Source filing: View source filing
Reporting owner signature: /s/ Vanina de Verneuil, Attorney-In-Fact

Key filing fact

Mark Eisner filed Form 4 for Vir Biotechnology, Inc. (VIR) on 17 Jul 2025.

Key facts

This page summarizes Mark Eisner's Form 4 filing for Vir Biotechnology, Inc. (VIR).
2 reported transactions and 0 derivative rows are listed below.
Accepted by SEC: 17 Jul 2025, 18:46.

Change

Previous filing in this sequence was filed on 25 Feb 2025.
Current net transaction value: -$56,791.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001834161 Primary reporting owner

Eisner Mark

Relationship: EVP and Chief Medical Officer
Address: C/O VIR BIOTECHNOLOGY, INC., 1800 OWENS STREET, SUITE 900, SAN FRANCISCO
Signature: /s/ Vanina de Verneuil, Attorney-In-Fact
Signature date: 17 Jul 2025

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

VIR transaction

Common Stock

Sale

Transaction value: $37,162
Shares: -6,796
Change %: -5.9%
Price: $5.47
Shares after: 108,204
Date: 15 Jul 2025
Ownership: Direct
Footnotes: F1

VIR transaction

Common Stock

Sale

Transaction value: $19,629
Shares: -3,586
Change %: -3.3%
Price: $5.47
Shares after: 104,618
Date: 17 Jul 2025
Ownership: Direct
Footnotes: F2, F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Rule 10b5-1 trading plan

These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.

Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).

Explanation of responses 3 footnotes

Footnote F1

Represents the automatic sale of shares to cover the Issuer's tax withholding and remittance obligation in connection with the vesting of restricted stock units.

Footnote F2

Represents shares sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 5, 2024.

Footnote F3

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.41 to $5.53, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.